crovalimab-akkz 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies 5814 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • crovalimab
  • crovalimab-akkz
  • piasky
  • RG6107
  • SKY59
Crovalimab is a recombinant humanized monoclonal IgG1 antibody that binds to complement protein C5. By binding to C5, crovalimab inhibits its cleavage into C5a and C5b, thereby preventing formation of the membrane attack complex (MAC).
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
24.30 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 26, 2024 PMDA Chugai Pharmaceutical Co., Ltd.
June 20, 2024 FDA Genentech, Inc.
Aug. 22, 2024 EMA Roche Registration GmbH

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Type III immune complex mediated reaction 92.60 67.07 11 60 571 42620693

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Type III immune complex mediated reaction 142.60 64.04 17 141 1036 110588105

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AJ07 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Complement inhibitors
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D051056 Complement Inactivating Agents
FDA EPC N0000194109 Complement C5 Inhibitor
FDA MoA N0000194110 Complement C5 Inhibitors
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

L04AJ Complement inhibitors 10 drugs
avacopandanicopaneculizumabiptacopanpegcetacoplanpozelimabravulizumabsutimlimabvilobelimabzilucoplan

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Paroxysmal nocturnal hemoglobinuria indication 1963002 DOID:0060284
Unresolved serious infection caused by Neisseria meningitidis contraindication 23511006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Complement C5 Secreted COMPLEMENT INHIBITOR Kd 9.76 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEMBL4594316 ChEMBL_ID
DB16128 DRUGBANK_ID
4043279 VANDF
4043280 VANDF
C5925709 UMLSCUI
CHEBI:757815 CHEBI
1917321-26-6 SECONDARY_CAS_RN
386417 MMSL
42925 MMSL
d10196 MMSL
019794 NDDF
12790 IUPHAR_LIGAND_ID
10882 INN_ID
2686619 RXNORM
43789811000001106 SNOMEDCT_US
C000731754 MESH_SUPPLEMENTAL_RECORD_UI
D11696 KEGG_DRUG
H9KH1GP3UU UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Piasky HUMAN PRESCRIPTION DRUG LABEL 1 50242-115 INJECTION, SOLUTION 340 mg SUBCUTANEOUS BLA 29 sections